Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Accumulated Expenses (2016 - 2025)

Lisata Therapeutics' Accumulated Expenses history spans 13 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 52.6% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 52.6%, while the annual FY2025 figure was $2.1 million, 52.6% down from the prior year.
  • Accumulated Expenses reached $2.1 million in Q4 2025 per LSTA's latest filing, down from $3.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.3 million in Q4 2024 to a low of $2.1 million in Q4 2025.
  • Average Accumulated Expenses over 3 years is $3.7 million, with a median of $3.9 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: rose 8.25% in 2024, then plummeted 52.6% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $4.2 million in 2023, then grew by 3.84% to $4.3 million in 2024, then tumbled by 52.6% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Accumulated Expenses are $2.1 million (Q4 2025), $3.9 million (Q3 2025), and $3.5 million (Q2 2025).